3-(羟甲基)-1,3-二氢吲哚-2-酮 | 2005-90-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-(羟甲基)-1,3-二氢吲哚-2-酮
• 英文名称: 2-oxindole-3-methanol
• 英文别名: 3-hydroxymethyl-1,3-dihydro-indol-2-one；3-Hydroxymethyl-2(3H)indolon；3-Hydroxymethyl-oxindol；3-Hydroxymethyloxindol；3-(Hydroxymethyl)-1,3-dihydro-2h-indol-2-one；3-(hydroxymethyl)-1,3-dihydroindol-2-one
• CAS: 2005-90-5
• 化学式: C₉H₉NO₂
• 分子量: 163.176
• InChiKey: VTCQUDZNRKSJFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  3-(羟甲基)-1,3-二氢吲哚-2-酮 、 3-[5-(benzyloxy)-2-hydroxyphenyl]-1-[(5-chlorothiophen-2-yl)methyl]-1,3-dihydro-2H-indol-2-one 、 聚合甲醛 、 sodium hydroxide 在 盐酸 、 乙酸乙酯 、 氯化铵 、 Brine 、 Sodium sulfate-III 、 乙醚 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 以to afford 3-[5-(benzyloxy)-2-hydroxyphenyl]-1-[(5-chlorothiphen-2-yl)methyl]3-(hydroxymethyl)-1,3-dihydro-2H-indol-2-one (2.71 g, 91%) as a colourless solid的产率得到3-[5-(benzyloxy)-2-hydroxyphenyl]-1-[(5-chloro-2-thienyl)methyl]-3-hydroxymethyl-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

  摘要：

  本发明涉及螺环-氧吲哚化合物，作为其立体异构体，对映异构体，互变异构体或其混合物；或其药学上可接受的盐，溶剂化合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，如疼痛。

  公开号：

  US20150291623A1
• 作为产物：
  描述：

  3-吲哚乙酸 在 氧气 作用下， 以 水 为溶剂， 生成 3-吲哚甲醛 、 吲哚-3-甲醇 、 3-亚甲基氧化吲哚 、 3-(羟甲基)-1,3-二氢吲哚-2-酮
  参考文献：
  名称：

  Photooxidative decarboxylation of indole-3-acetic acid by pyrimido(5,4-g)pteridine N-oxide as a biomimetic reaction.

  摘要：

  在吡啶唑[5, 4-g]哌啶N-氧化物（1a）的存在下，对吲哚-3-乙酸（2）进行辐照，可以生成吲哚-3-羧醛（3）作为主要产物。提出并讨论了光氧化脱羧反应的反应序列，并与植物中2转化为3的生物转化过程相关联。

  DOI：

  10.1248/cpb.37.3239

文献信息

• PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES
  申请人：Bednarek Pawel

  公开号：US20090028796A1

  公开（公告）日：2009-01-29

  The present invention is directed to pesticidal compositions comprising indole derivatives. These indole derivatives are especially active against phytopathogenic fungi. Furthermore, the invention relates to the use of indole derivatives for the production of pesticides and the use of the compositions according to the invention as pesticides. The present invention is also directed to a process for producing a pesticidal composition and to pesticidal compositions prepared by this process. In addition, the invention relates to a process for preventing or combating pests and to a process for protecting plants against pests, especially against phytopathogenic fungi. Further, the invention is directed to plants or seeds as well as objects or materials which have been protected against pests by treatment with a composition according to the invention. Further, the invention is directed to a method for identifying a substance having pesticidal activity. Further, the invention is directed to a method of identifying the mode of action of and/or of providing binding proteins for a pesticidal compound of the present invention. Finally, the invention is directed to a method for diagnosing pest infection of a plant and to the use of a pesticidal compound of the present invention as diagnostic markers.

  本发明涉及包含吲哚衍生物的杀虫组合物。这些吲哚衍生物特别对植物病原真菌具有活性。此外，本发明涉及使用吲哚衍生物制备杀虫剂以及使用本发明中的组合物作为杀虫剂。本发明还涉及制备杀虫组合物的过程以及通过该过程制备的杀虫组合物。此外，本发明还涉及预防或对抗害虫的过程以及保护植物免受害虫，特别是植物病原真菌的过程。此外，本发明还涉及经过本发明中的组合物处理后受到保护的植物或种子以及物体或材料。本发明还涉及识别具有杀虫活性的物质的方法。此外，本发明还涉及识别本发明中杀虫化合物的作用方式和/或提供结合蛋白的方法。最后，本发明涉及诊断植物害虫感染的方法以及使用本发明中的杀虫化合物作为诊断标记的方法。
• Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
  申请人：VEIJLEN N.V.

  公开号：US10716778B2

  公开（公告）日：2020-07-21

  The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.

  本公开涉及一种或多种能够提高血清中胰岛素样生长因子1（IGF-1）水平的化合物用于制备治疗组合物，特别是以食品补充剂的形式，用于治疗患有严重疲劳和疲惫症状、倦怠和慢性疲劳综合征的患者。同样的组合物还可用于抑郁症、老年痴呆症、肠易激综合征、骨质疏松症、2 型糖尿病患者，或用于抗衰老、免疫疗法和运动后恢复。该成分还可用于兽医领域，提高动物的生长速度和免疫力。
• PREPARATION OF BIOLOGICALLY ACTIVE 3-METHYLENEOXINDOLE AND DEFINITION OF ITS APPLICATION IN STIMULATION OF PLANT GROWTH AND TISSUE REPAIR
  申请人：——

  公开号：US20020055171A1

  公开（公告）日：2002-05-09

  Identification of the true nature and metabolic action of 3 -methyleneoxindole (MO), a naturally occurring catabolite of the plant auxin, indole- 3 -acetic acid (IAA). Description of the two novel methods of synthesis of MO which produce the pure, biologically active auxin compound of MO. Discovery and description of the causes for the erroneous classification of MO as an inert compound with no auxin activity. These findings and methods of synthesis correct the ubiquitous theoretical errors which have driven scientific investigation and plant science research of plant auxins for nearly forty years. Researchers have failed to observe the auxin activity of MO because of the use of standard but incorrect synthetic techniques which have consistently produced impure forms of 3 -bromooxindole- 3 -acetic acid ( 3 -Brox), the synthetic precursor of MO. In addition, the use of dimethylsulfooxide as a solvent for MO has been identified as a major source of contamination of MO during synthesis. This invention describes two novel methods for synthesizing (MO). By using purified MO and avoiding the use of dimethylsulfoxide, it was found that the resulting MO product to be 100 to 1,00 fold more effective than IAA in promoting rooting in plant cuttings; supporting tissue differentiation and growth in stage I, stage II and stage III media used for the micropropagation of explants; promoting the formation of callus tissue over wounded plant parts; and, stimulating the production of interstitial tissue between scion and rootstock to increase the success rate for grafting. Therefore, this invention identifies MO as the dominant auxin in shoot acceleration, root development, wound sealing and scion acceptance. Finally, the correct pathway from IAA to MO is presented.

  确定 3-羟基-2-甲基丙烷的真正性质和代谢作用 3 -亚甲基吲哚（MO）的真正性质和代谢作用。 3 -乙酸（IAA）的天然代谢产物。介绍合成 MO 的两种新方法，这两种方法可生产出纯净的、具有生物活性的 MO auxin 化合物。发现并描述了将 MO 错误地归类为无植物生长素活性的惰性化合物的原因。这些发现和合成方法纠正了近四十年来推动植物辅助素科学调查和植物科学研究的无处不在的理论错误。 研究人员之所以未能观察到 MO 的辅助素活性，是因为他们使用了标准但不正确的合成技术，这些技术一直在生产不纯的 MO 3 -溴氧化吲哚- 3 -乙酸 3 -Brox），这是 MO 的合成前体。此外，使用二甲基亚砜作为 MO 的溶剂已被确定为 MO 在合成过程中的主要污染源。 本发明介绍了两种合成（MO）的新方法。通过使用纯化的 MO 和避免使用二甲基亚砜，发现在促进植物插条生根；支持用于外植体微繁殖的 I 期、II 期和 III 期培养基中的组织分化和生长；促进受伤植物部分形成胼胝组织；以及刺激接穗和砧木之间产生间隙组织以提高嫁接成功率方面，所得到的 MO 产品比 IAA 的效果高 100 至 1,00 倍。因此，本发明确定 MO 是芽加速、根系发育、伤口封闭和接穗接受过程中的主要辅助素。 最后，介绍了从 IAA 到 MO 的正确途径。
• Tissue-specific endothelial membrane proteins
  申请人：——

  公开号：US20030021792A1

  公开（公告）日：2003-01-30

  Methods and compositions for targeting of pharmaceuticals or other therapeutics to specific tissues using tissue-specific endothelial membrane proteins are provided. The compositions comprise a therapeutic complex composed of a ligand, a linker, and a therapeutic moiety, where the therapeutic moiety can enter the cell. The ligand can be an antibody or other molecule that binds to a tissue-specific protein on the endothelial membrane of a specific tissue. The ligand need not activate a receptor, but may activate endocytosis. The therapeutic moiety can be a drug, gene, antisense oligonucleotide, contrast agent, protein, toxin, or any type of molecule that acts on the specific tissue. The linker can be a liposome or a cleavable or noncleavable chemical molecule. Alternatively, the linker may simply be the bond between the ligand and the therapeutic moiety. Alternatively, a lipophilic prodrug may be cleaved and may enter the cell due to its lipophilic properties.

  本发明提供了利用组织特异性内皮膜蛋白将药物或其他疗法靶向特定组织的方法和组合物。这些组合物包括由配体、连接体和治疗分子组成的治疗复合物，其中治疗分子可进入细胞。配体可以是与特定组织内皮膜上的组织特异性蛋白结合的抗体或其他分子。配体不必激活受体，但可激活内吞作用。治疗分子可以是药物、基因、反义寡核苷酸、造影剂、蛋白质、毒素或任何作用于特定组织的分子。连接体可以是脂质体或可裂解或不可裂解的化学分子。或者，连接体可以只是配体与治疗分子之间的键。另外，亲脂性原药可被裂解，并可因其亲脂性进入细胞。
• Lumen-exposed molecules and methods for targeted delivery
  申请人：Utah Ventures II L.P.

  公开号：US20040146516A1

  公开（公告）日：2004-07-29

  The present invention provides novel methods and kits for labeling and isolating tissue-specific or organ-specific lumen-exposed molecules. In addition, the present invention provides tissue-specific or organ-specific lumen-exposed polypeptides, which were isolated by the methods herein. Furthermore the present invention provides therapeutic complexes comprising ligands that bind the tissue-specific or organ-specific lumen-exposed polypeptides attached to therapeutic moieties for targeted treatment and prevention.

  本发明提供了标记和分离组织特异性或器官特异性腔隙暴露分子的新方法和试剂盒。此外，本发明还提供了组织特异性或器官特异性腔隙暴露多肽，这些多肽是通过本发明的方法分离出来的。此外，本发明还提供了由配体组成的治疗复合物，这些配体可结合附着在治疗分子上的组织特异性或器官特异性腔隙暴露多肽，用于靶向治疗和预防。